ElectroCore Reports Strong Q1 Growth and Strategic Expansion

Electrocore ( (ECOR) ) has released its Q1 earnings. Here is a breakdown of the information Electrocore presented to its investors.

ElectroCore, Inc. is a commercial-stage bioelectronic technology company focused on developing non-invasive solutions to improve health and quality of life. Operating primarily in the healthcare sector, the company is known for its innovative bioelectronic therapies.

In its first quarter of 2025, ElectroCore reported a 23% increase in net sales, reaching $6.7 million compared to the previous year. This growth was bolstered by the acquisition of NeuroMetrix, which added approximately $170,000 in sales for the quarter. The company continues to expand its bioelectronic platform, positioning itself as a significant player in the market.

Key financial highlights include a gross profit of $5.7 million, maintaining an 85% gross margin. The company’s operating expenses rose to $9.5 million due to increased selling, marketing, and administrative costs, alongside non-recurring expenses related to the NeuroMetrix acquisition. Despite a GAAP net loss of $3.9 million, ElectroCore improved its adjusted EBITDA net loss to $3.1 million, reflecting operational efficiencies.

Looking forward, ElectroCore anticipates total revenue of approximately $30 million for the full year 2025, with expectations for NeuroMetrix to contribute significantly by year-end. The company’s strategic focus on expanding its product line and market presence suggests a promising trajectory in the bioelectronic technology space.